• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

中重度溃疡性结肠炎患者口服抗CD3（OKT3）单克隆抗体相关的免疫改变

Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis.

作者信息

Boden Elisa K, Canavan James B, Moran Christopher J, McCann Katelyn, Dunn William A, Farraye Francis A, Ananthakrishnan Ashwin N, Yajnik Vijay, Gandhi Roopali, Nguyen Deanna D, Bhan Atul K, Weiner Howard L, Korzenik Joshua R, Snapper Scott B

机构信息

Division of Gastroenterology, Virginia Mason Medical Center, Seattle, WA.

Benaroya Research Institute, Seattle, WA.

出版信息

Crohns Colitis 360. 2019 Jul;1(2):otz009. doi: 10.1093/crocol/otz009. Epub 2019 Jun 7.

DOI:10.1093/crocol/otz009
PMID:31423487
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6690423/
Abstract

AIM

The aim of this study was to determine the immunologic effects and safety of oral anti-CD3 in patients with ulcerative colitis (UC).

METHODS

An open-label pilot study of orally delivered anti-CD3 was performed in patients with moderate-to-severe UC. The primary end points were changes in immunologic parameters and evaluation for safety.

RESULTS

Six subjects received oral OKT3. Biologic effects of oral anti-CD3 included significantly increased proliferation in response to anti-CD3 and anti-inflammatory gene expression profile in peripheral blood mononuclear cells. No serious treatment-related adverse events occurred.

CONCLUSION

Orally delivered anti-CD3 resulted in immunologic changes in patients with UC.

摘要

目的

本研究旨在确定口服抗CD3对溃疡性结肠炎（UC）患者的免疫作用及安全性。

方法

对中重度UC患者进行了一项口服抗CD3的开放标签试点研究。主要终点是免疫参数的变化及安全性评估。

结果

6名受试者接受了口服OKT3。口服抗CD3的生物学效应包括外周血单核细胞对抗CD3反应的增殖显著增加以及抗炎基因表达谱变化。未发生严重的治疗相关不良事件。

结论

口服抗CD3可使UC患者出现免疫变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f9d/6690423/6abc9aab4877/otz009f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f9d/6690423/6abc9aab4877/otz009f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f9d/6690423/6abc9aab4877/otz009f0001.jpg

相似文献

1
Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis.中重度溃疡性结肠炎患者口服抗CD3（OKT3）单克隆抗体相关的免疫改变
Crohns Colitis 360. 2019 Jul;1(2):otz009. doi: 10.1093/crocol/otz009. Epub 2019 Jun 7.
2
Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells.口服 OKT3 单克隆抗体可诱导人类受试者的 T 细胞和树突状细胞产生剂量依赖性免疫效应。
J Clin Immunol. 2010 Jan;30(1):167-77. doi: 10.1007/s10875-009-9323-7. Epub 2009 Sep 16.
3
Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial.口服 OKT3 MAb 治疗 NASH 患者可促进调节性 T 细胞诱导，减轻胰岛素抵抗：一项 IIa 期双盲安慰剂对照试验结果。
J Clin Immunol. 2015 May;35(4):399-407. doi: 10.1007/s10875-015-0160-6. Epub 2015 Apr 17.
4
Novel humanized anti-CD3 antibodies induce a predominantly immunoregulatory profile in human peripheral blood mononuclear cells.新型人源化抗CD3抗体在人外周血单核细胞中诱导出主要的免疫调节特征。
Immunol Lett. 2009 Aug 15;125(2):129-36. doi: 10.1016/j.imlet.2009.06.009. Epub 2009 Jun 30.
5
Etrolizumab for induction of remission in ulcerative colitis.艾托珠单抗用于诱导溃疡性结肠炎缓解
Cochrane Database Syst Rev. 2015 Dec 2;2015(12):CD011661. doi: 10.1002/14651858.CD011661.pub2.
6
OKT3 induction via idiotypic networks of mirror-image immunosuppressive antiimmunoglobulins in renal transplant recipients.通过肾移植受者中镜像免疫抑制性抗免疫球蛋白的独特型网络诱导OKT3。
Transplantation. 1990 Feb;49(2):408-15. doi: 10.1097/00007890-199002000-00036.
7
Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.抗CD3抗体序贯大剂量推注白细胞介素-2用于转移性黑色素瘤和晚期肾细胞癌患者的I B期临床试验：临床和免疫效应
J Clin Oncol. 1993 Aug;11(8):1496-505. doi: 10.1200/JCO.1993.11.8.1496.
8
Immunologic monitoring with Orthoclone OKT3 therapy.使用Orthoclone OKT3疗法进行免疫监测。
J Heart Transplant. 1989 Sep-Oct;8(5):371-80.
9
An oral CD3-specific antibody suppresses T-cell-induced colitis and alters cytokine responses to T-cell activation in mice.一种口服 CD3 特异性抗体可抑制 T 细胞诱导的结肠炎，并改变对 T 细胞活化的细胞因子反应。
Gastroenterology. 2012 Nov;143(5):1298-1307. doi: 10.1053/j.gastro.2012.07.019. Epub 2012 Jul 20.
10
Anti-CD3 antibodies OKT3 and hOKT3gamma1(Ala-Ala) induce proliferation of T cells but impair expansion of alloreactive T cells; aspecifc T cell proliferation induced by anti-CD3 antibodies correlates with impaired expansion of alloreactive T cells.抗CD3抗体OKT3和hOKT3γ1（丙氨酸-丙氨酸）可诱导T细胞增殖，但会损害同种反应性T细胞的扩增；抗CD3抗体诱导的特异性T细胞增殖与同种反应性T细胞扩增受损相关。
Int Immunopharmacol. 2005 Jan;5(1):155-62. doi: 10.1016/j.intimp.2004.09.023.

引用本文的文献

1
Suppression of anti-drug antibody formation against coagulation factor VIII by oral delivery of anti-CD3 monoclonal antibody in hemophilia A mice.口服抗 CD3 单克隆抗体抑制血友病 A 小鼠抗凝血因子 VIII 抗体的产生。
Cell Immunol. 2023 Mar;385:104675. doi: 10.1016/j.cellimm.2023.104675. Epub 2023 Jan 30.
2
Nasal administration of anti-CD3 monoclonal antibody modulates effector CD8+ T cell function and induces a regulatory response in T cells in human subjects.鼻内给予抗 CD3 单克隆抗体可调节效应性 CD8+T 细胞的功能，并在人体 T 细胞中诱导调节性反应。
Front Immunol. 2022 Nov 23;13:956907. doi: 10.3389/fimmu.2022.956907. eCollection 2022.
3

本文引用的文献

1
Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226.表达受体TIGIT和CD226的人类调节性T细胞的不同表型
J Immunol. 2015 Jul 1;195(1):145-55. doi: 10.4049/jimmunol.1402381. Epub 2015 May 20.
2
Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial.口服 OKT3 MAb 治疗 NASH 患者可促进调节性 T 细胞诱导，减轻胰岛素抵抗：一项 IIa 期双盲安慰剂对照试验结果。
J Clin Immunol. 2015 May;35(4):399-407. doi: 10.1007/s10875-015-0160-6. Epub 2015 Apr 17.
3
Alternative Routes of Administration for Therapeutic Antibodies-State of the Art.
治疗性抗体的替代给药途径——最新技术水平
Antibodies (Basel). 2022 Aug 26;11(3):56. doi: 10.3390/antib11030056.
4
Landscape of new drugs and targets in inflammatory bowel disease.炎症性肠病新药和新靶点的研究进展。
United European Gastroenterol J. 2022 Dec;10(10):1129-1166. doi: 10.1002/ueg2.12305. Epub 2022 Sep 16.
5
How could nanobiotechnology improve treatment outcomes of anti-TNF-α therapy in inflammatory bowel disease? Current knowledge, future directions.纳米生物技术如何改善炎症性肠病抗 TNF-α 治疗的疗效？ 当前的知识、未来的方向。
J Nanobiotechnology. 2021 Oct 29;19(1):346. doi: 10.1186/s12951-021-01090-1.
6
Therapeutic antibodies - natural and pathological barriers and strategies to overcome them.治疗性抗体——天然和病理性障碍及其克服策略。
Pharmacol Ther. 2022 May;233:108022. doi: 10.1016/j.pharmthera.2021.108022. Epub 2021 Oct 20.
7
Delivery of Orally Administered Digestible Antibodies Using Nanoparticles.口服可消化抗体的纳米颗粒递送。
Int J Mol Sci. 2021 Mar 25;22(7):3349. doi: 10.3390/ijms22073349.
8
The Therapeutic Potential of Regulatory T Cells: Challenges and Opportunities.调节性 T 细胞的治疗潜力：挑战与机遇。
Front Immunol. 2021 Jan 15;11:585819. doi: 10.3389/fimmu.2020.585819. eCollection 2020.
9
An Update on Pharmaceutical Strategies for Oral Delivery of Therapeutic Peptides and Proteins in Adults and Pediatrics.成人及儿科治疗性肽和蛋白质口服给药的药物策略更新
Children (Basel). 2020 Dec 19;7(12):307. doi: 10.3390/children7120307.
10
[Not Available].[无可用信息]。
Allergo J. 2020;29(4):32-61. doi: 10.1007/s15007-020-2550-1. Epub 2020 Jun 24.
CD161 defines a transcriptional and functional phenotype across distinct human T cell lineages.
CD161定义了不同人类T细胞谱系中的一种转录和功能表型。
Cell Rep. 2014 Nov 6;9(3):1075-88. doi: 10.1016/j.celrep.2014.09.045. Epub 2014 Oct 23.
4
Oral anti-CD3 immunotherapy for HCV-nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase-2a placebo-controlled trial.口服抗CD3免疫疗法对丙型肝炎病毒无应答者安全，可促进调节性T细胞并降低病毒载量和肝酶水平：一项2a期安慰剂对照试验的结果
J Viral Hepat. 2015 Aug;22(8):651-7. doi: 10.1111/jvh.12369. Epub 2014 Nov 21.
5
Combination treatment with anti-CD20 and oral anti-CD3 prevents and reverses autoimmune diabetes.抗 CD20 联合治疗和口服抗 CD3 可预防和逆转自身免疫性糖尿病。
Diabetes. 2013 Aug;62(8):2849-58. doi: 10.2337/db12-1175. Epub 2013 Feb 27.
6
Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS.通过调控具有独特 miRNA 基因特征的炎症性单核细胞可改善小鼠 ALS。
J Clin Invest. 2012 Sep;122(9):3063-87. doi: 10.1172/JCI62636. Epub 2012 Aug 6.
7
An oral CD3-specific antibody suppresses T-cell-induced colitis and alters cytokine responses to T-cell activation in mice.一种口服 CD3 特异性抗体可抑制 T 细胞诱导的结肠炎，并改变对 T 细胞活化的细胞因子反应。
Gastroenterology. 2012 Nov;143(5):1298-1307. doi: 10.1053/j.gastro.2012.07.019. Epub 2012 Jul 20.
8
Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis.抗 CD3 抗体维得利珠单抗对静脉注射皮质类固醇难治性溃疡性结肠炎患者无效。
Gut. 2010 Nov;59(11):1485-92. doi: 10.1136/gut.2009.205443.
9
Mucosal anti-CD3 monoclonal antibody attenuates collagen-induced arthritis that is associated with induction of LAP+ regulatory T cells and is enhanced by administration of an emulsome-based Th2-skewing adjuvant.黏膜抗 CD3 单克隆抗体可减轻胶原诱导性关节炎，其与诱导 LAP+调节性 T 细胞有关，并可通过施用基于乳剂的 Th2 偏向佐剂增强。
J Immunol. 2010 Sep 15;185(6):3401-7. doi: 10.4049/jimmunol.1000836. Epub 2010 Aug 18.
10
Inflammatory bowel disease.炎症性肠病
N Engl J Med. 2009 Nov 19;361(21):2066-78. doi: 10.1056/NEJMra0804647.